Commercial Services and Supplies
Company Overview of Cystic Fibrosis Foundation
Cystic Fibrosis Foundation operates as a subsidiary of Walgreens Boots Alliance, Inc.
6931 Arlington Road
Bethesda, MD 20814
Founded in 1955
Key Executives for Cystic Fibrosis Foundation
Chief Executive Officer and President
National Director of Special Projects
Compensation as of Fiscal Year 2016.
Cystic Fibrosis Foundation Key Developments
The Cystic Fibrosis Foundation Opens One-Of-a-Kind Research Lab
Sep 16 16
The Cystic Fibrosis Foundation announced the official opening of a new, one-of-a kind research facility in Lexington, Mass. Operated by Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), an affiliate of the CF Foundation, the lab is designed to identify and test potential therapies for rare and common mutations of cystic fibrosis, with the ultimate goal of bringing new treatments to people living with the disease. CF is a complex, fatal disease that affects about 30,000 adults and children in the United States and 70,000 people worldwide. It is caused by more than 1,700 genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Although the majority of individuals with CF have at least one copy of the most common mutation, 5% of people carry only nonsense and other types of rare mutations that do not respond to existing drugs – known as CFTR modulators – that treat the underlying cause of the disease. Building on CFFT’s expertise in cell culture, gene editing and stem cell research, the lab’s 25 scientists will spearhead a new initiative to collect and grow cells from people with CF who have nonsense and other rare mutations. These cells will be critical for identifying treatments for rare mutations, and will be made available to academic institutions and pharmaceutical companies to expedite the development of new medications. The team also will continue to screen promising compounds in order to identify the ones that hold the potential for correcting CFTR mutations.
Cystic Fibrosis Foundation Appoints Marc Ginsky as Executive Vice President and Chief Operating Officer
May 2 16
The Cystic Fibrosis Foundation announced the appointment of Marc Ginsky as executive vice president and chief operating officer. Mr. Ginsky will oversee the Foundation’s day-to-day operations with a focus on field management, information technology and the Foundation’s infrastructure. He will report to and work alongside Dr. Preston W. Campbell, III, president and chief executive officer, to advance the Foundation’s mission to cure cystic fibrosis and help people with the disease live longer, healthier lives. He joins the Foundation from Covance. He served as the vice president and general manager of the Market Access Services division since 2007. Prior to that, he worked in Covance’s legal department in roles of increasing responsibility from 1998 to 2006, supporting all aspects of the drug development and market access businesses of the company. Before joining Covance, Marc was a corporate attorney in private practice for 10 years.
Cystic Fibrosis Foundation Appoints John Wetherell to the Board
Mar 17 16
Intellectual Property and Life Sciences partner John Wetherell has been appointed to the board of the Cystic Fibrosis Foundation's (CFF) San Diego chapter. In addition to his role as the local leader of Pillsbury's San Diego Intellectual Property practice, Dr. Wetherell is the leader of the Stem Cell Outlook and Planning Effort (SCOPE) and the author of several works dealing with patent protection for stem cell innovations. Before becoming an attorney, Dr. Wetherell was a research scientist and manager in the biotechnology industry.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries